Name of journal: *World Journal of Diabetes*

ESPS Manuscript NO: 11090

Columns: EDITORIAL

**Pancreatic steatosis: Is it related to either obesity or diabetes mellitus?**

Pezzilli R *et al.* Pancreatic steatosis

Raffaele Pezzilli, Lucia Calculli

**Raffaele Pezzilli,** Department of Digestive Diseases and Internal Medicine, Sant’Orsola-Malpighi Hospital, 40138 Bologna, Italy

**Lucia Calculli,** Department of Radiology, Sant’Orsola-Malpighi Hospital, 40138 Bologna, Italy

**Author contributions:** Pezzilli R and Calculli L analyzed the literature data and interpreted the results; Pezzilli R designed the study and wrote the manuscript; Pezzilli R and Calculli L approved the final version of the manuscript.

**Correspondence to:** Raffaele Pezzilli, MD, Department of Digestive Diseases and Internal Medicine, Sant’Orsola-Malpighi Hospital, Via Massarenti 9, 40138 Bologna, Italy. raffaele.pezzilli@aosp.bo.it

**Telephone:** +39-051-6364148 **Fax:** +39-051-6364148

**Received:** May 4, 2014 **Revised:** May 25, 2014

**Accepted:** June 27, 2014

**Published online:**

**Abstract**

## The accumulation of fat in the pancreatic gland has been referred to using various synonyms, such as pancreatic lipomatosis, fatty replacement, fatty infiltration, fatty pancreas, lipomatous pseudohypertrophy, non-alcoholic fatty pancreatic disease and pancreatic steatosis We believe that pancreatic steatosis is the best description of fat accumulation in the pancreatic gland without fat replacement, and this term also describes the possibility that the fat accumulation is a reversible process. A review of the existing literature was carried out, and it was found that there was notable evidence from both the pathological and the imaging point of view that pancreatic steatosis is an increasing problem due to the increasing incidence of obesity. The conclusion was that pancreatic steatosis was easily detectable using modern imaging techniques, such as ultrasonography, endoscopic ultrasonography, computed tomography and magnetic resonance imaging. Pancreatic steatosis was not due to the presence of diabetes mellitus but was highly associated with the metabolic syndrome. The possible presence of steatopancreatitis should be better evaluated, especially regarding the inflammatory cascade, and additional studies are needed which are capable of assessing whether non-alcoholic steatopancreatitis really exists as does non-alcoholic steatohepatitis. Finally, the presence of exocrine pancreatic function should be extensively evaluated in patients with pancreatic steatosis.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words:** Computed tomography; Endoscopic ultrasonography; Magnetic resonance imaging; Metabolic syndrome; Pancreatic steatosis; Pathology; Type 2 diabetes mellitus; Ultrasonography

**Core tip:** Pancreatic steatosis is easily detectable using modern imaging techniques, such as ultrasonography, endoscopic ultrasonography, computed tomography and magnetic resonance imaging. It is not due to the presence of diabetes mellitus but is highly associated with the metabolic syndrome. The possible presence of steatopancreatitis should be better evaluated, especially regarding the inflammatory cascade, and additional studies are needed which are capable of assessing whether non-alcoholic steatopancreatitis really exists as does non-alcoholic steatohepatitis. Additional studies regarding the exocrine pancreatic function in patients with pancreatic steatosis are needed.

Pezzilli R, Calculli L. Pancreatic steatosis: Is it related to either obesity or diabetes mellitus? *World J Diabetes* 2014; In press

**INTRODUCTION**

Obesity has become a major problem of social and psychological dimensions and it affects all age and socioeconomic groups. It was calculated that, in 1995, there were approximately 200 million obese adults worldwide and another 18 million children under five classified as overweight. In 2000, the number of obese adults increased to over 300 million, and there are also obese subjects in developing countries; it has been estimated that over 115 million people suffer from obesity-related problems[1]. Due to the worldwide presence of this problem, the term “globesity” has been coined by the WHO[2].

Obesity is associated with an elevated number of diseases, and the top 10 obesity-related diseases are high blood pressure, diabetes, heart disease, brain disease, cancer, infertility, back pain due to injury to the most vulnerable parts of the spine, skin infections, gastric ulcers and gallstones.

In the livers of obese patients, a bright liver is seen at ultrasound along with increased levels of hepatic enzymes, such as alanine aminotransferase, aspartate aminotransferase or γ-glutamyltransferase; their prevalence increases progressively with increasing body mass index (BMI)[3]. At liver biopsy, subjects with moderate or severe fatty change, lipogranulomas, focal necroses or parenchymal inflammation are significantly more obese than patients without these changes[4]. Two key components of the metabolic syndrome, glucose and triglycerides, are overproduced by a fatty liver, and the liver is a key determinant of metabolic abnormalities[5]. The effects of the metabolic syndrome on the exocrine pancreas have been less investigated than that of the liver. Thus, we have reviewed the existing data in the literature regarding the effects of obesity and diabetes mellitus on the exocrine pancreas.

**DEFINITION OF PANCREATIC STEATOSIS**

The accumulation of fat in the pancreatic gland (Figures 1 and 2) has been referred to using various synonyms, such as pancreatic lipomatosis, fatty replacement, fatty infiltration, fatty pancreas, lipomatous pseudohypertrophy, non-alcoholic fatty pancreatic disease and pancreatic steatosis[6]. According to the well-written paper of Smits and van Geenen[6], we believe that pancreatic steatosis is the best description of fat accumulation in the pancreatic gland without fat replacement, and this term also describes the possibility that fat accumulation is a reversible process.

**HISTOLOGICAL ASPECTS OF EXOCRINE PANCREATIC STEATOSIS: THE ERA OF AUTOPTIC STUDIES**

The first extensive study on this topic was that of Ogilvie who evaluated the exocrine pancreas of 19 obese patients (17 of whom were females, having a mean age of 52 years with a range from 27 to 67 years) and in 19 non-obese subjests (11 of whom were female, having a mean age of 48.5 years with a range from 19 to 67 years[7]. He found that all pancreatic glands in the controls and in the majority of obese patients showed varying degrees of adiposity, and that the degree of adiposity was higher in obese patients (mean 17.1%, range 0-48.5) than in the controls (mean 9.3%, range 2.5-23.6). Regarding the endocrine pancreas, Ogilvie found hypertrophy of the islet of Langerhans in obese patients with respect to the controls. After the study of Ogilvie, the problem of a fatty pancreas was neglected for several years and, in 1978, Olsen evaluated the presence of a fatty pancreas in 394 autopsies[8]. He graded the pancreatic fat into four categories: Grade 1 sections with few scattered fat cells in the exocrine parenchyma, Grade 4 with the partial or total replacement of exocrine lobules with fatty tissue, and Grades 2 and 3 with a number of fat cells between Grades 1 and 4. The cadavers were divided into three groups: those having below normal weight, those having normal weight and those having above normal weight. He found a relationship between the content of fatty pancreatic cells and age, and between the presence of fat in the pancreas and being overweight. However, in these two studies, the presence of fat in the pancreas was related to the presence of obesity, but not to the presence of diabetes mellitus.

More recently, it has been demonstrated in postmortem material collected from 80 patients that interlobular and total pancreatic fat were both related to the non-alcoholic fatty liver disease activity score in patients without steatogenic medication but, when corrected for body mass index, no relationship was found. Thus, total pancreatic fat was a significant predictor of the presence of non-alcoholic fatty liver disease, and the presence of intralobular pancreatic fat was related to non-alcoholic steatohepatitis whereas total fat was not; this relationship seemed to be mediated by general obesity[9].

**THE IMAGING ASPECTS OF EXOCRINE PANCREATIC STEATOSIS: THE ERA OF “*IN VIVO*” AUTOPTIC STUDIES**

With the introduction of increasingly refined imaging techniques into clinical practice, it is possible to perform increasingly sophisticated imaging studies which are, in some ways, similar to autopsies carried out “*in vivo”*.

The most largely used technique is ultrasonography; Lee *et al*[10] used this technique to evaluate the fat content of the pancreas. They used the increase echogenicity of the pancreatic body over kidney echogenicity as the index of a fatty pancreas, and they found that a fatty pancreas is related only to the metabolic syndrome. These data were also confirmed using an endoscopic ultrasonography in a study comprising 60 patients and 60 controls[11]; in this latter study, hepatic steatosis, alcohol use and an increased BMI were predictors of pancreatic steatosis fat[11].

In one study, the pancreatic volume from birth to advanced age (100 years old) was evaluated in a retrospective study[12]; the authors studied by computed tomography 133 subjects with under 20 years of age, 1721 adults over 20 years of age and 165 patients having type-2 diabetes and, in these patients, the fat within the pancreatic gland was also evaluated. What were the results? The pancreas volume increased relatively rapidly in childhood, changed little from 20 to 60 years of age and then declined in subjects over 60 years of age; the pancreatic volume was 16%-32% greater in obese patients as compared to non-obese patients, and the increase in the volume of the pancreas in obese patients was similar in males as compared to females[12]. The fat volume was also increased in obese patients, and this effect remained so until the age of 70[12]. Of importance, both the total and the parenchymal pancreatic volume were decreased in diabetic patients, and there was no difference in fat volume between patients with type-2 diabetes and non-diabetics; in addition, in cadavers in whom an autopsied pancreas was available, the pancreatic fat was similar between diabetic and non-diabetic subjects but, in non-diabetic patients, the fat increased with obesity and age[12].

The best imaging technique for evaluating the presence of fat in the pancreas is [magnetic resonance imaging](http://suoxie.911cha.com/N3F3.html) (MRI). There are at least three methods utilized to measure the fat in the pancreas using MRI; the most common is to utilize the frequency shift between the water and the fat resonances to generate in-phase and opposed-phase images in which the signal of the water and fat net magnetization vectors are at a maximum or a minimum. The Dixon method which visualizes the water and fat fractions by the post-processing of the in-phase and opposed-phase spin echo images and leads to water- and fat-selection. The last method, called the spectral-spatial excitation technique, combines chemical shift selectivity with simultaneous slice-selective excitation in gradient-echo imaging sequences. Schwenzer *et al*[13] found that the fat content calculated from images recorded with the fat-selective spectral-spatial gradient-echo sequence correlated well with the fat fraction determined with in-phase/opposed-phase imaging. In addition, the fat percentage increased from the head to the tail of the pancreas as shown in Figure 3. Finally, in another study, the pancreatic fat increased with BMI only in non-diabetic patients[14], confirming the previously published data of[12, 15-17].

**RELATIONSHIPS BETWEEN INSULIN AND PANCREATIC STEATOSIS**

Insulin secretion increases parallel to insulin resistance in order to maintain normal glucose homeostasis in obese patients; the patients that are predisposed to diabetes fail to compensate adequately for the greater insulin requirements[18]. Fat accumulation in the pancreatic islets leads to a decreased insulin secretion and might explain why insulin resistant people cannot encounter the higher demands of insulin and then develop type 2 diabetes mellitus[19-24]. In addition, a greater proportion of pancreatic fat was associated with increased insulin levels in obese nondiabetic subjects. This may indicate that the toxic effect of pancreatic fat accumulation might require a long time before manifesting in impaired β-cell function and it has been assessed that pancreatic β-cell damage is present for more than a decade before diabetes is diagnosed[25].

**PANCREATIC STEATOSIS AND EXOCRINE PANCREATIC FUNCTION**

Exocrine pancreatic insufficiency has been reported in 14.3% of patients with type 2 diabetes mellitus; it is usually only of a mild to a moderate degree and does not lead to clinically overt steatorrhea in the majority of diabetics[26]; however, in patients with pancreatic steatosis the data are scarce and are mainly based on case reports. Lozano *et al*[27] have reported two adult patients with weight loss and massive steatorrhea in whom abdominal computed tomograms demonstrated severe pancreatic steatosis; oral pancreatic enzyme replacement in association with cimetidine led to a marked reduction of steatorrhea and weight gain in both patients. Using computed tomography, So *et al*[28] found a pancreas completely replaced by fat in a 57-year-old woman having a 22-year history of chronic diarrhea. Aubert *et al*[29] reported two cases of diffuse and primitive fat replacement of the exocrine pancreas associated with chronic diarrhea and steatorrhea in whom the administration of pancreatic extracts improved symptoms. Thus, pancreatic functional studies are necessary to establish the degree of fat replacement capable of determining exocrine pancreatic insufficiency.

**CONCLUSION**

Pancreatic steatosis is easy detectable using modern imaging techniques, such as ultrasonography, endoscopic ultrasonography, computed tomography and magnetic resonance imaging. Pancreatic steatosis is not due to the presence of diabetes mellitus but is highly associated with the metabolic syndrome. The possible presence of steatopancreatitis should be better evaluated, especially regarding the inflammatory mediators involved, and additional studies are need capable of assessing whether non-alcoholic steatopancreatitis really exists as does non-alcoholic steatohepatitis. Finally, the presence of exocrine pancreatic function should be extensively evaluated in patients with pancreatic steatosis.

**REFERENCES**

1 http: //www.who.int/nutrition/topics/obesity/en/

2 http: //apps.who.int/bmi/index.jsp

3 **Marchesini G**, Moscatiello S, Di Domizio S, Forlani G. Obesity-associated liver disease. *J Clin Endocrinol Metab* 2008; **93**: S74-S80 [PMID: 18987273 DOI: 10.1210/jc.2008-1399]

4 **Andersen T**, Christoffersen P, Gluud C. The liver in consecutive patients with morbid obesity: a clinical, morphological, and biochemical study. *Int J Obes* 1984; **8**: 107-115 [PMID: 6724792]

5 **Yki-Järvinen H**. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. *Lancet Diabetes Endocrinol* 2014; **pii**: S2213-8587(14)70032-4 [PMID: 24731669]

6 **Smits MM**, van Geenen EJ. The clinical significance of pancreatic steatosis. *Nat Rev Gastroenterol Hepatol* 2011; **8**: 169-177 [PMID: 21304475 DOI: 10.1038/nrgastro.2011.4]

7 **Ogilvie RF**. The islands of Langerhans in 19 cases of obesity. *J Pathol* 1933; **37**: 473-81 [DOI: 10.1002/path.1700370314]

8 **Olsen TS**. Lipomatosis of the pancreas in autopsy material and its relation to age and overweight. *Acta Pathol Microbiol Scand A* 1978; **86A**: 367-373 [PMID: 716899 DOI: 10.1111/j.1699-0463.1978.tb02058.x]

9 **van Geenen EJ**, Smits MM, Schreuder TC, van der Peet DL, Bloemena E, Mulder CJ. Nonalcoholic fatty liver disease is related to nonalcoholic fatty pancreas disease. *Pancreas* 2010; **39**: 1185-1190 [PMID: 20871475 DOI: 10.1097/MPA.0b013e3181f6fce2]

10 **Lee JS**, Kim SH, Jun DW, Han JH, Jang EC, Park JY, Son BK, Kim SH, Jo YJ, Park YS, Kim YS. Clinical implications of fatty pancreas: correlations between fatty pancreas and metabolic syndrome. *World J Gastroenterol* 2009; **15**: 1869-1875 [PMID: 19370785 DOI: 10.3748/wjg.15.1869]

11 **Al-Haddad M**, Khashab M, Zyromski N, Pungpapong S, Wallace MB, Scolapio J, Woodward T, Noh K, Raimondo M. Risk factors for hyperechogenic pancreas on endoscopic ultrasound: a case-control study. *Pancreas* 2009; **38**: 672-675 [PMID: 19506531 DOI: 10.1097/MPA.0b013e3181a9d5af]

12 **Saisho Y**, Butler AE, Meier JJ, Monchamp T, Allen-Auerbach M, Rizza RA, Butler PC. Pancreas volumes in humans from birth to age one hundred taking into account sex, obesity, and presence of type-2 diabetes. *Clin Anat* 2007; **20**: 933-942 [PMID: 17879305 DOI: 10.1002/ca.20543]

13 **Schwenzer NF**, Machann J, Martirosian P, Stefan N, Schraml C, Fritsche A, Claussen CD, Schick F. Quantification of pancreatic lipomatosis and liver steatosis by MRI: comparison of in/opposed-phase and spectral-spatial excitation techniques. *Invest Radiol* 2008; **43**: 330-337 [PMID: 18424954 DOI: 10.1097/RLI.0b013e31816a88c6]

14 **Tushuizen ME**, Bunck MC, Pouwels PJ, Bontemps S, van Waesberghe JH, Schindhelm RK, Mari A, Heine RJ, Diamant M. Pancreatic fat content and beta-cell function in men with and without type 2 diabetes. *Diabetes Care* 2007; **30**: 2916-2921 [PMID: 17666465 DOI: 10.2337/dc07-0326]

15 **Saisho Y**, Butler AE, Butler PC. Pancreatic fat content and beta-cell function in men with and without type 2 diabetes: response to Tushuizen et al. *Diabetes Care* 2008; **31**: e38; author reply e39 [PMID: 18445718 DOI: 10.2337/dc08-0044]

16 **Wong VW**, Wong GL, Yeung DK, Abrigo JM, Kong AP, Chan RS, Chim AM, Shen J, Ho CS, Woo J, Chu WC, Chan HL. Fatty pancreas, insulin resistance, and β-cell function: a population study using fat-water magnetic resonance imaging. *Am J Gastroenterol* 2014; **109**: 589-597 [PMID: 24492753 DOI: 10.1038/ajg.2014.1]

17 **Heni M**, Machann J, Staiger H, Schwenzer NF, Peter A, Schick F, Claussen CD, Stefan N, Häring HU, Fritsche A. Pancreatic fat is negatively associated with insulin secretion in individuals with impaired fasting glucose and/or impaired glucose tolerance: a nuclear magnetic resonance study. *Diabetes Metab Res Rev* 2010; **26**: 200-205 [PMID: 20225188 DOI: 10.1002/dmrr.1073]

18 **Poitout V**. Beta-cell lipotoxicity: burning fat into heat? *Endocrinology* 2004; **145**: 3563-3565 [PMID: 15265823 DOI: 10.1210/en.2004-0479]

19 **Ritz-Laser B**, Meda P, Constant I, Klages N, Charollais A, Morales A, Magnan C, Ktorza A, Philippe J. Glucose-induced preproinsulin gene expression is inhibited by the free fatty acid palmitate. *Endocrinology* 1999; **140**: 4005-4014 [PMID: 10465270 DOI: 10.1210/en.140.9.4005]

20 **Lameloise N**, Muzzin P, Prentki M, Assimacopoulos-Jeannet F. Uncoupling protein 2: a possible link between fatty acid excess and impaired glucose-induced insulin secretion? *Diabetes* 2001; **50**: 803-809 [PMID: 11289045 DOI: 10.2337/diabetes.50.4.803]

21 **Bränström R**, Leibiger IB, Leibiger B, Corkey BE, Berggren PO, Larsson O. Long chain coenzyme A esters activate the pore-forming subunit (Kir6. 2) of the ATP-regulated potassium channel. *J Biol Chem* 1998; **273**: 31395-31400 [PMID: 9813050 DOI: 10.1074/jbc.273.47.31395]

22 **Liang Y**, Buettger C, Berner DK, Matschinsky FM. Chronic effect of fatty acids on insulin release is not through the alteration of glucose metabolism in a pancreatic beta-cell line (beta HC9). *Diabetologia* 1997; **40**: 1018-1027 [PMID: 9300238 DOI: 10.1007/s001250050783]

23 **El-Assaad W**, Buteau J, Peyot ML, Nolan C, Roduit R, Hardy S, Joly E, Dbaibo G, Rosenberg L, Prentki M. Saturated fatty acids synergize with elevated glucose to cause pancreatic beta-cell death. *Endocrinology* 2003; **144**: 4154-4163 [PMID: 12933690 DOI: 10.1210/en.2003-0410]

24 **Maedler K**, Oberholzer J, Bucher P, Spinas GA, Donath MY. Monounsaturated fatty acids prevent the deleterious effects of palmitate and high glucose on human pancreatic beta-cell turnover and function. *Diabetes* 2003; **52**: 726-733 [PMID: 12606514 DOI: 10.2337/diabetes.52.3.726]

25 **Oakes ND**, Bell KS, Furler SM, Camilleri S, Saha AK, Ruderman NB, Chisholm DJ, Kraegen EW. Diet-induced muscle insulin resistance in rats is ameliorated by acute dietary lipid withdrawal or a single bout of exercise: parallel relationship between insulin stimulation of glucose uptake and suppression of long-chain fatty acyl-CoA. *Diabetes* 1997; **46**: 2022-2028 [PMID: 9392490 DOI: 10.2337/diab.46.12.2022]

26 **Pezzilli R**, Andriulli A, Bassi C, Balzano G, Cantore M, Delle Fave G, Falconi M. Exocrine pancreatic insufficiency in adults: a shared position statement of the Italian Association for the Study of the Pancreas. *World J Gastroenterol* 2013; **19**: 7930-7946 [PMID: 24307787 DOI: 10.3748/wjg.v19.i44.7930]

27 **Lozano M**, Navarro S, Pérez-Ayuso R, Llach J, Ayuso C, Guevara MC, Ros E. Lipomatosis of the pancreas: an unusual cause of massive steatorrhea. *Pancreas* 1988; **3**: 580-582 [PMID: 3186686 DOI: 10.1097/00006676-198810000-00012]

28 **So CB**, Cooperberg PL, Gibney RG, Bogoch A. Sonographic findings in pancreatic lipomatosis. *AJR Am J Roentgenol* 1987; **149**: 67-68 [PMID: 3296712 DOI: 10.2214/ajr.149.1.67]

29 **Aubert A**, Gornet JM, Hammel P, Lévy P, O'Toole D, Ruszniewski P, Modigliani R, Lémann M. [Diffuse primary fat replacement of the pancreas: an unusual cause of steatorrhea]. *Gastroenterol Clin Biol* 2007; **31**: 303-306 [PMID: 17396091 DOI: 10.1016/S0399-8320(07)89379-1]

**P-Reviewers:** Ali O, de Oliveira CPMS, Sasaoka T, Tziomalos K **S-Editor:** Ji FF

**L-Editor: E-Editor:**



**Figure 1** [**Magnetic resonance imaging**](http://suoxie.911cha.com/N3F3.html) **using FSR T2 sequence, showing the presence of fat infiltration in body and tail of the pancreas.** The fat present is hyperintense (white) as the abdominal fat, while the pancreatic normal tissue is hypointense.



**Figure 2** [**Magnetic resonance imaging**](http://suoxie.911cha.com/N3F3.html) **during the arterial phase showing the presence of diffuse fat infiltration in the body and tail of the pancreas.** The fat present in the pancreatic gland is black using LAVA sequence (LAVA combines contrast-enhanced, multi-phase imaging of the abdomen with high resolution, large coverage and uniform fat suppression).



**Figure 3 Percent of fat fraction according to three pancreatic regions; data are reported as mean and standard deviation) (modified from reference [13]).**